In infectious disease diagnostics, speed has always mattered. But speed alone is no longer enough.

For hospitals, laboratories and infection control teams, the real question is not simply whether a test can produce a fast result. The more important question is whether that result arrives early enough to change a clinical decision.

• Should a patient with suspected tuberculosis be isolated immediately?

• Is a newly admitted patient carrying MRSA, VRE or carbapenemase-producing organisms?

• Can clinicians adjust treatment before broad-spectrum antibiotics are used unnecessarily?

• Can HPV or STI testing be completed within the same visit, with counselling and follow-up arranged before the patient leaves?

These are not laboratory questions alone. They are workflow questions. They affect admission, triage, isolation, antimicrobial stewardship, patient flow and public health response.

This is where molecular point-of-care testing is becoming increasingly important. It does not replace the central laboratory. Rather, it brings selected molecular results closer to the moment when clinical decisions are made.

1. Why molecular POCT matters now

Conventional microbiology remains essential. Culture, phenotypic susceptibility testing, central laboratory PCR and sequencing all play important roles in diagnosis and surveillance. But they often operate on a timeline that does not match the pace of frontline care.

A result that returns after two or three days may still be clinically valuable. Yet in many cases, the most important decisions have already been taken by then: the patient has been admitted, moved to a ward, started on treatment, or placed in contact with other vulnerable patients.

Molecular POCT addresses this timing gap.

Its value lies in providing actionable information earlier, especially for diseases and conditions where early decisions affect infection control, treatment selection and patient management. Tuberculosis, antimicrobial resistance, respiratory infections, sexually transmitted infections and HPV screening are among the clearest examples.

The next phase of POCT is therefore not only about faster testing. It is about decision-ready diagnostics.

2. Cepheid set the benchmark

Any serious discussion of molecular POCT must acknowledge Cepheid’s GeneXpert platform.

GeneXpert became a global reference not because it introduced PCR to clinical medicine, but because it made complex molecular testing usable in routine settings. Sample preparation, nucleic acid extraction, amplification, detection and result reporting were integrated into a closed cartridge-based system.

That design changed expectations.

Xpert MTB/RIF Ultra, for example, allows detection of Mycobacterium tuberculosis complex and rifampicin resistance-associated mutations within a clinically meaningful timeframe. In many settings, this can influence isolation, treatment initiation and public health management.

The platform’s strength also lies in its menu. Beyond TB, Cepheid has built assays for drug-resistant TB, carbapenemase-producing organisms, VRE, MRSA, HPV, respiratory pathogens and other infectious disease applications.

This is the standard that new entrants must be measured against. The issue is not whether they can perform PCR. The issue is whether they can offer a complete, reliable and deployable molecular testing model: instrument, cartridge, assay menu, workflow, evidence, regulatory pathway, training and support.

3. The Chinese POCT opportunity is broader than price

Chinese IVD companies are often viewed through the lens of cost. That is understandable, but incomplete.

The more important shift is that leading Chinese POCT companies are moving from single rapid tests to platform-based diagnostics. Their strengths are not limited to lower manufacturing costs. They also include supply chain depth, faster product iteration, broad menu development and experience serving highly varied healthcare environments.

This matters because most healthcare systems are not made up only of large academic hospitals.

Community clinics, regional hospitals, long-term care facilities, mobile screening units, private specialist practices and border health settings all have different constraints. They need systems that are easier to operate, easier to maintain and financially sustainable.

A molecular POCT platform that is compact, cartridge-based and able to support multiple infectious disease assays may fit these settings better than a model designed only around high-volume central laboratories.

That is where Chinese companies may have a meaningful role to play: not simply as lower-cost alternatives, but as contributors to a more distributed diagnostic model.

4. Wondfo as a representative example

Wondfo is one of the more relevant examples of this transition.

The company built its global reputation in rapid testing and conventional POCT. Over time, it expanded into fluorescence immunoassays, chemiluminescence, coagulation, blood gas, HbA1c, pathology and molecular diagnostics.

Its U-Card Dx / U-CardDx molecular platform reflects a broader direction in China’s IVD sector: moving from screening-oriented POCT towards decision-support diagnostics.

Based on publicly available product information, the U-Card Dx system uses a closed cartridge format and integrates molecular testing workflows into a simplified platform. Wondfo’s newer U-CardDx 200 system has been presented as an automated rapid molecular diagnostic system combining microfluidics, magnetic bead-based nucleic acid extraction and real-time qPCR.

The important point is not that Wondfo has created another PCR device. The important point is that the company is building a menu around real clinical use cases: MTB, MTB/RIF, MTB resistance markers, MRSA/SA, carbapenem resistance, VRE, HPV, STI and respiratory pathogens.

That menu strategy is what makes the platform clinically relevant.

5. TB remains a defining use case

Tuberculosis is one of the strongest examples of why molecular POCT matters.

The clinical challenge is not only detecting MTB. Clinicians also need early information on drug resistance, particularly rifampicin resistance, and in many cases resistance associated with isoniazid and fluoroquinolones.

Culture and phenotypic drug susceptibility testing remain indispensable. But they take time. Molecular diagnostics can provide earlier signals that help clinicians move faster on isolation, treatment planning and public health notification.

Cepheid’s Xpert MTB/RIF Ultra is already well established in this space. It has shaped the way many institutions think about rapid TB diagnosis.

Wondfo’s MTB, MTB&RIF and MTB INH&FQs assays appear to follow a similar clinical direction: from pathogen detection towards earlier resistance assessment. This is the right direction for a molecular POCT platform, because TB management depends not only on whether MTB is present, but also on whether resistance is likely.

For markets such as Singapore, TB may not carry the same burden as in high-incidence countries, but it remains a relevant public health and infection control issue. Rapid molecular testing can still play a role in hospitals, high-risk screening, long-term care transfers and selected institutional settings.

6. AMR screening may be the next major battleground

Antimicrobial resistance is one of the most important growth areas for molecular POCT.

Hospitals do not only need to know whether a patient is infected. They need to know whether the patient may be carrying organisms that change infection control procedures.

MRSA, VRE and carbapenemase-producing organisms are especially important because they affect isolation, bed management, ICU workflows, pre-operative planning and outbreak investigation.

Cepheid’s Xpert Carba-R is a useful reference point. It targets major carbapenemase gene families such as KPC, NDM, VIM, IMP and OXA-48-like variants. The value of this type of assay is operational as much as diagnostic: it helps infection control teams act earlier.

Wondfo’s menu includes MRSA/SA, Carba and VRE assays. This suggests that Chinese molecular POCT platforms are no longer focused only on respiratory infections or single-pathogen testing. They are moving into the core territory of hospital infection prevention.

If these platforms can demonstrate strong analytical performance, reliable workflow and robust local support, they may help make AMR screening more accessible beyond large tertiary centres.

That matters in Southeast Asia, where healthcare capabilities vary widely between institutions and where practical deployment is often as important as technical sophistication.

7. Platforms are won by menus, not single assays

A molecular POCT platform rarely succeeds because of one assay alone.

Hospitals and clinics invest in systems that can solve more than one problem. A platform that supports TB, AMR screening, respiratory pathogens, HPV, STI and gastrointestinal infections naturally becomes more useful across departments.

HPV is a good example. As cervical cancer screening continues to shift towards HPV molecular testing, faster testing may support same-visit counselling, triage and follow-up planning.

STI testing is similar. Rapid detection of CT, NG, MG and TV can reduce loss to follow-up and support earlier treatment.

Respiratory testing remains relevant even after the acute phase of the COVID-19 pandemic. Influenza, RSV and broader respiratory panels continue to influence patient flow, isolation decisions and antiviral use.

The question is not whether these tests exist. They do.

The question is whether healthcare providers can deploy them in a way that is practical, affordable and integrated into daily care.

This is where a broad, cartridge-based molecular POCT menu becomes strategically important.

8. Comparing Wondfo with Cepheid: what should actually be compared?

It would be too simplistic to describe Wondfo as a direct replacement for Cepheid.

Cepheid has strong global recognition, extensive clinical validation, a mature installed base and deep experience across infectious disease programmes. That position was built over many years.

A more useful comparison should focus on practical dimensions:

Assay menu
Can the platform cover clinically important areas such as TB, AMR, HPV, STI and respiratory pathogens?

Workflow
Does the system reduce hands-on time, contamination risk and operator burden?

Deployment flexibility
Can it be used outside large central laboratories, including clinics, smaller hospitals and institutional screening settings?

Total cost of ownership
Beyond the instrument price, what are the costs of cartridges, maintenance, quality control, training, downtime, storage and support?

Regulatory readiness
Are the relevant products supported by appropriate documentation, performance evidence and registration pathways in the target market?

Clinical evidence
How well do the assays perform against accepted reference methods in real-world samples and local workflows?

This is the level at which serious evaluation should take place.

For Chinese molecular POCT platforms, the opportunity is not to win by price alone. It is to prove that they can deliver reliable molecular diagnostics in settings where existing options may be too costly, too centralised or too difficult to scale.

9. Relevance for Singapore and Southeast Asia

Singapore has a highly regulated and quality-driven healthcare system. Any new diagnostic platform must meet expectations for evidence, compliance, safety and service reliability.

That means new entrants cannot rely on pricing arguments alone.

At the same time, there is room for complementary models.

Large hospitals will continue to depend on central laboratories for high-throughput testing, confirmatory diagnostics, full susceptibility testing and quality oversight. But rapid molecular tools may still add value in emergency departments, admission screening, ICUs, infectious disease services and outbreak response.

Private clinics may value shorter turnaround time and improved patient experience.

Long-term care facilities may need simpler tools for infection risk management and referral decisions.

Regional healthcare networks may benefit from distributed testing capacity, especially when fast decisions are needed before samples can be processed centrally.

In this context, Chinese molecular POCT platforms should not be positioned merely as substitutes for established international brands. Their more realistic role is to complement existing systems and fill specific workflow gaps.

10. The road ahead

Molecular POCT is not about moving the entire laboratory to the bedside.

It is about moving selected, high-value molecular answers closer to clinical decision-making.

The central laboratory will remain essential. It provides scale, complexity, quality oversight, confirmatory testing and advanced diagnostics.

Molecular POCT plays a different role. It helps clinicians act sooner.

Cepheid has already shown that closed-cartridge molecular diagnostics can change infectious disease workflows. Companies such as Wondfo are now testing whether similar capabilities can become more accessible, more flexible and better suited to diverse healthcare environments.

For Singapore and Southeast Asia, the next question is not whether one platform replaces another. The more important question is how healthcare systems can build faster, more resilient and more practical diagnostic pathways.

At Vitania, we see molecular POCT as part of that wider transformation: a bridge between laboratory science and real-world clinical decision-making.

References and Source Materials

1. World Health Organization. WHO consolidated guidelines on tuberculosis: Module 3: Diagnosis.

2. World Health Organization. WHO operational handbook on tuberculosis: Module 3: Diagnosis.

3. World Health Organization. Global Tuberculosis Report.

4. Communicable Diseases Agency Singapore. Update on tuberculosis situation in Singapore.

5. Cepheid. Xpert MTB/RIF Ultra product information.

6. Cepheid. Xpert MTB/XDR product information.

7. Cepheid. Xpert Carba-R product information.

8. Cepheid. Xpert vanA/vanB product information.

9. Cepheid. Xpert MRSA NxG product information.

10. Cepheid. Xpert HPV / Xpert HPV v2 product information.

11. Cepheid. Molecular Diagnostic Test Menu.

12. Wondfo Biotech. Molecular Diagnostics Platform.

13. Wondfo Biotech. Wondfo U-Card Dx Automated Rapid Molecular Diagnostic Instrument.

14. Wondfo Biotech. U-CardDx 200 Automated Rapid Molecular Diagnostic System.

15. Wondfo Biotech. 15-Minute Molecular Testing: Wondfo Showcases U-CardDx 200 at ESCMID 2026.

16. Wondfo Biotech. U-Card Dx HPV Test product information.

17. Wondfo Biotech. U-Card Dx HPV16/18 Test product information.

18. Wondfo Biotech. U-Card Dx CT/NG Test product information.

19. Wondfo Biotech. U-Card Dx CT/NG/MG/TV Test product information.

20. Wondfo Biotech. U-Card Dx 2019-nCoV/Flu Test product information.

21. FIND. Evaluation of Wondfo U-Card Dx 2019-nCoV/Flu Test.

22. Chakravorty S. et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin. mBio. 2017.

23. Dorman S.E. et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance.

24. Bonomo R.A. et al. Carbapenemase-Producing Organisms: A Global Scourge. Clinical Infectious Diseases. 2018.

25. Zhou M. et al. Active Surveillance of Carbapenemase-Producing Organisms Colonization With Xpert Carba-R Assay Plus Positive Patient Isolation. Frontiers in Cellular and Infection Microbiology. 2019.

26. European Centre for Disease Prevention and Control. Carbapenem-resistant Enterobacteriaceae risk assessment.

27. Centers for Disease Control and Prevention. Carbapenem-resistant Enterobacterales information for healthcare facilities.

28. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare settings.

29. World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance.

30. Clinical and Laboratory Standards Institute. Molecular diagnostic methods for infectious diseases.

31. Singapore Clinical Tuberculosis Guidelines Development Team. Singapore tuberculosis clinical management guidelines. Annals, Academy of Medicine, Singapore. 2024.

32. International Agency for Research on Cancer / World Health Organization. Cervical cancer elimination strategy and HPV screening guidance.

33. World Health Organization. Global strategy to accelerate the elimination of cervical cancer as a public health problem.

34. FIND. Landscape and evaluation resources for near-patient molecular diagnostics.

35. U.S. International Trade Administration. China healthcare and IVD market overview.

✉️ Email Address:

info@vitania.net

📍Singapore Headquarters:

14, Robinson Road, #08-01A
Far East Finance Building
Singapore 048545

📍United Kingdom Office:

71–75 Shelton Street
London, WC2H 9JQ
United Kingdom

Contact us